Haematological malignancies implications during the times of the COVID‑19 pandemic (Review)

Papakonstantinou,Eleni; Dragoumani,Konstantina; Efthimiadou,Aspasia; Palaiogeorgou,Anastasia Marina; Pierouli,Katerina; Mitsis,Thanasis; Chrousos,George P.; Bacopoulou,Flora; Vlachakis,Dimitrios

doi:10.3892/ol.2021.13117

Haematological malignancies implications during the times of the COVID‑19 pandemic (Review)

Authors:
- Eleni Papakonstantinou
- Konstantina Dragoumani
- Aspasia Efthimiadou
- Anastasia Marina Palaiogeorgou
- Katerina Pierouli
- Thanasis Mitsis
- George P. Chrousos
- Flora Bacopoulou
- Dimitrios Vlachakis
View Affiliations

Affiliations: Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, 11855 Athens, Greece, Hellenic Agricultural Organization‑Demeter, Institute of Soil and Water Resources, Department of Soil Science of Athens, 14123 Lycovrisi, Greece, University Research Institute of Maternal and Child Health and Precision Medicine, and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, 11527 Athens, Greece
Published online on: October 29, 2021 https://doi.org/10.3892/ol.2021.13117
Article Number: 856
Copyright: © Papakonstantinou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The COVID‑19 pandemic has complicated current healthcare services for cancer patients. Patients with haematological malignancies specifically seem vulnerable to SARS‑CoV‑2 infection due to their immunosuppressed status. The COVID‑19 pandemic influences every step of the assessment and treatment of a haematological malignancy. Clinicians must adhere to strict policies to not spread the virus to their patients while they must also adjust their workflow for maximum productivity. These difficulties accentuate the ever‑present need to improve the healthcare services for cancer patients. This improvement is needed not only to combat the problems that arose from the COVID‑19 pandemic but also to establish a framework for the management of patients with haematological malignancies in potential future pandemics.

View Figures

View References

1	Pearce L: Haematological cancers. Nurs Stand. 30:152016. View Article : Google Scholar
2	Pérez GB, Calaf GM, Villalba MTM, Prieto KS and Burgos FC: Frequency of hematologic malignancies in the population of Arica, Chile. Oncol Lett. 18:5637–5643. 2019.PubMed/NCBI
3	Taylor J, Xiao W and Abdel-Wahab O: Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 130:410–423. 2017. View Article : Google Scholar : PubMed/NCBI
4	The Lancet Haematology, . The global burden of haematological diseases. Lancet Haematol. 5:e12018. View Article : Google Scholar : PubMed/NCBI
5	Krok-Schoen JL, Fisher JL, Stephens JA, Mims A, Ayyappan S, Woyach JA and Rosko AE: Incidence and survival of hematological cancers among adults ages ≥75 years. Cancer Med. 7:3425–3433. 2018. View Article : Google Scholar : PubMed/NCBI
6	Egesie OJ, Agaba PA, Silas OA, Achenbach C, Zoakah A, Agbaji OO, Madaki JA, Okeke EN, Hou L, Sagay AS and Murphy R: Presentation and survival in patients with hematologic malignancies in Jos, Nigeria: A retrospective cohort analysis. J Med Trop. 20:49–56. 2018. View Article : Google Scholar : PubMed/NCBI
7	Khayr W, Haddad RY and Noor SA: Infections in hematological malignancies. Dis Mon. 58:239–249. 2012. View Article : Google Scholar : PubMed/NCBI
8	Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, Megawati D, Hayati Z, Wagner AL and Mudatsir M: Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 13:667–673. 2020. View Article : Google Scholar : PubMed/NCBI
9	Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM and Bahreini E: A comprehensive review of COVID-19 characteristics. Biol Proced Online. 22:192020. View Article : Google Scholar : PubMed/NCBI
10	Muralidar S, Ambi SV, Sekaran S and Krishnan UM: The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 179:85–100. 2020. View Article : Google Scholar : PubMed/NCBI
11	Neagu M, Calina D, Docea AO, Constantin C, Filippini T, Vinceti M, Drakoulis N, Poulas K, Nikolouzakis TK, Spandidos DA and Tsatsakis A: Back to basics in COVID-19: Antigens and antibodies-completing the puzzle. J Cell Mol Med. 25:4523–4533. 2021. View Article : Google Scholar : PubMed/NCBI
12	Sarkar C, Mondal M, Torequl Islam M, Martorell M, Docea AO, Maroyi A, Sharifi-Rad J and Calina D: Potential therapeutic options for COVID-19: Current status, challenges, and future perspectives. Front Pharmacol. 11:5728702020. View Article : Google Scholar : PubMed/NCBI
13	Kostoff RN, Kanduc D, Porter AL, Shoenfeld Y, Calina D, Briggs MB, Spandidos DA and Tsatsakis A: Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety. Toxicol Rep. 7:1448–1458. 2020. View Article : Google Scholar : PubMed/NCBI
14	Rudrapal M, Khairnar SJ, Borse LB and Jadhav AG: Coronavirus disease-2019 (COVID-19): An updated review. Drug Res (Stuttg). 70:389–400. 2020. View Article : Google Scholar : PubMed/NCBI
15	Calina D, Hernández AF, Hartung T, Egorov AM, Izotov BN, Nikolouzakis TK, Tsatsakis A, Vlachoyiannopoulos PG and Docea AO: Challenges and scientific prospects of the newest generation of mRNA-based vaccines against SARS-CoV-2. Life (Basel). 11:9072021.PubMed/NCBI
16	Islam MT, Salehi B, Karampelas O, Sharifi-Rad J, Docea AO, Martorell M and Calina D: High skin melanin content, vitamin D deficiency and immunity: Potential interference for severity of COVID-19. Farmacia. 68:970–983. 2020. View Article : Google Scholar
17	Lotfi M, Hamblin MR and Rezaei N: COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 508:254–266. 2020. View Article : Google Scholar : PubMed/NCBI
18	Giammaria D and Pajewski A: Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic? J Glob Health. 10:0103772020. View Article : Google Scholar : PubMed/NCBI
19	WHO, . Weekly epidemiological update-2 February 2021. Journal;2021.
20	Lee ACK and Morling JR: COVID-19 vaccine dilemmas. Public Health. 2021. View Article : Google Scholar
21	Badiani AA, Patel JA, Ziolkowski K and Nielsen FBH: Pfizer: The miracle vaccine for COVID-19? Public Health Pract (Oxf). 1:1000612020. View Article : Google Scholar : PubMed/NCBI
22	Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, et al: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (review). Int J Mol Med. 46:3–16. 2020. View Article : Google Scholar : PubMed/NCBI
23	Calina D, Sarkar C, Arsene AL, Salehi B, Docea AO, Mondal M, Islam MT, Zali A and Sharifi-Rad J: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol Res. 68:315–324. 2020. View Article : Google Scholar : PubMed/NCBI
24	Alfano V and Ercolano S: The efficacy of lockdown against COVID-19: A cross-country panel analysis. Appl Health Econ Health Policy. 18:509–517. 2020. View Article : Google Scholar : PubMed/NCBI
25	Papakonstantinou E, Pierouli K, Mitsis T, Diakou KI, Palaiogeorgou AM, Bacopoulou F, Chrousos GP, Eliopoulos E and Vlachakis D: COVID-19 global social lockdowns: Energy-related, psychological, epigenetic, health and environmental impacts (review). Int J Epigen. 1:82021. View Article : Google Scholar
26	Calina D, Hartung T, Mardare I, Mitroi M, Poulas K, Tsatsakis A, Rogoveanu I and Docea AO: COVID-19 pandemic and alcohol consumption: Impacts and interconnections. Toxicol Rep. 8:529–535. 2021. View Article : Google Scholar : PubMed/NCBI
27	Moraliyage H, De Silva D, Ranasinghe W, Adikari A, Alahakoon D, Prasad R, Lawrentschuk N and Bolton D: Cancer in lockdown: Impact of the COVID-19 pandemic on patients with cancer. Oncologist. 26:e342–e344. 2020.PubMed/NCBI
28	Rubinstein SM and Warner JL: COVID-19 and haematological malignancy: Navigating a narrow strait. Lancet Haematol. 7:e701–e703. 2020. View Article : Google Scholar : PubMed/NCBI
29	Wang Y, Duan Z, Ma Z, Mao Y, Li X, Wilson A, Qin H, Ou J, Peng K, Zhou F, et al: Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic. Transl Psychiatry. 10:2632020. View Article : Google Scholar : PubMed/NCBI
30	Islam MT, Hossen M, Kamaz Z, Zali A, Kumar M, Docea AO, Arsene AL, Călina D and Sharifi-Rad J: The role of hmgb1 in the immune response to sars-cov-2 infection: From pathogenesis towards a new potential therapeutic target. Farmacia. 69:621–634. 2021.
31	Isidori A, de Leval L, Gergis U, Musto P and Porcu P: Management of patients with hematologic malignancies during the COVID-19 pandemic: Practical considerations and lessons to be learned. Front Oncol. 10:14392020. View Article : Google Scholar : PubMed/NCBI
32	Binder AF, Handley NR, Wilde L, Palmisiano N and Lopez AM: Treating hematologic malignancies during a pandemic: Utilizing telehealth and digital technology to optimize care. Front Oncol. 10:11832020. View Article : Google Scholar : PubMed/NCBI
33	Jørgensen JT: Twenty years with personalized medicine: Past, present, and future of individualized pharmacotherapy. Oncologist. 24:e432–e440. 2019. View Article : Google Scholar : PubMed/NCBI
34	Divaris K: Fundamentals of precision medicine. Compend Contin Educ Dent. 38 (8 Suppl):S30–S32. 2017.PubMed/NCBI
35	Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA and Ferrari R: Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences. Brief Bioinform. 19:286–302. 2018. View Article : Google Scholar : PubMed/NCBI
36	D'Souza RN, Dunnwald M, Frazier-Bowers S, Polverini PJ, Wright JT, de Rouen T and Vieira AR; Translational Genetics Meeting Group, : Translational genetics: Advancing fronts for craniofacial health. J Dent Res. 92:1058–1064. 2013. View Article : Google Scholar : PubMed/NCBI
37	Vlachakis D and Kossida S: Antibody drug conjugate bioinformatics: Drug delivery through the letterbox. Comput Math Methods Med. 2013:2823982013. View Article : Google Scholar : PubMed/NCBI
38	Geres H and Kotchetkov R: Nursing in patients with hematological malignancies. Int J Hematol Oncol. 9:IJH242020. View Article : Google Scholar : PubMed/NCBI
39	Vedsted P and Olesen F: Early diagnosis of cancer-the role of general practice. Scand J Prim Health Care. 27:193–194. 2009. View Article : Google Scholar : PubMed/NCBI
40	Li J, Smith A, Crouch S, Oliver S and Roman E: Estimating the prevalence of hematological malignancies and precursor conditions using data from haematological malignancy research network (HMRN). Cancer Causes Control. 27:1019–1026. 2016. View Article : Google Scholar : PubMed/NCBI
41	Wang Y, Zhang B, Zhang X, Wang X, Cheng J and Chen B: Detection and identification of hematologic malignancies and solid tumors by an electrochemical technique. PLoS One. 11:e01538212016. View Article : Google Scholar : PubMed/NCBI
42	Dapkevičiūtė A, Šapoka V, Martynova E and Pečeliūnas V: Time from symptom onset to diagnosis and treatment among haematological malignancies: Influencing factors and associated negative outcomes. Medicina (Kaunas). 55:2382019. View Article : Google Scholar : PubMed/NCBI
43	Howell DA, Smith AG, Jack A, Patmore R, Macleod U, Mironska E and Roman E: Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: A report from the haematological malignancy research network. BMC Hematol. 13:92013. View Article : Google Scholar : PubMed/NCBI
44	Prakash G, Kaur A, Malhotra P, Khadwal A, Sharma P, Suri V, Varma N and Varma S: Current role of genetics in hematologic malignancies. Indian J Hematol Blood Transfus. 32:18–31. 2016. View Article : Google Scholar : PubMed/NCBI
45	Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S and Schwartz LM: Cancer survival: An overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014:145–186. 2014. View Article : Google Scholar : PubMed/NCBI
46	Gray TF, Temel JS and El-Jawahri A: Illness and prognostic understanding in patients with hematologic malignancies. Blood Rev. 45:1006922021. View Article : Google Scholar : PubMed/NCBI
47	Button E, Chan RJ, Chambers S, Butler J and Yates P: A systematic review of prognostic factors at the end of life for people with a hematological malignancy. BMC Cancer. 17:2132017. View Article : Google Scholar : PubMed/NCBI
48	de Vries VA, Müller MCA, Arbous MS, Biemond BJ, Blijlevens NMA, Kusadasi N, Span LRF, Vlaar APJ, van Westerloo DJ, Kluin-Nelemans HC, et al: Long-term outcome of patients with a hematologic malignancy and multiple organ failure admitted at the intensive care. Crit Care Med. 47:e120–e128. 2019. View Article : Google Scholar : PubMed/NCBI
49	Kansara RR and Speziali C: Immunotherapy in hematologic malignancies. Curr Oncol. 27 (Suppl 2):S124–S131. 2020. View Article : Google Scholar : PubMed/NCBI
50	Nelson MH and Paulos CM: Novel immunotherapies for hematologic malignancies. Immunol Rev. 263:90–105. 2015. View Article : Google Scholar : PubMed/NCBI
51	Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M and Krause DS: Bone marrow niches in haematological malignancies. Nat Rev Cancer. 20:285–298. 2020. View Article : Google Scholar : PubMed/NCBI
52	Boland MJ, Nazor KL and Loring JF: Epigenetic regulation of pluripotency and differentiation. Circ Res. 115:311–324. 2014. View Article : Google Scholar : PubMed/NCBI
53	Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
54	Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE and Boyiadzis M: DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies. Leukemia. 28:1774–1783. 2014. View Article : Google Scholar : PubMed/NCBI
55	Li KK, Luo LF, Shen Y, Xu J, Chen Z and Chen SJ: DNA methyltransferases in hematologic malignancies. Semin Hematol. 50:48–60. 2013. View Article : Google Scholar : PubMed/NCBI
56	Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, Kurosawa S, Iida S, Ibaraki T, Sato Y, et al: Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 27:1044–1052. 2013. View Article : Google Scholar : PubMed/NCBI
57	Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, et al: IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 119:1901–1903. 2012. View Article : Google Scholar : PubMed/NCBI
58	Lemonnier F, Couronné L, Parrens M, Jaïs JP, Travert M, Lamant L, Tournillac O, Rousset T, Fabiani B, Cairns RA, et al: Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 120:1466–1469. 2012. View Article : Google Scholar : PubMed/NCBI
59	Azad N, Zahnow CA, Rudin CM and Baylin SB: The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol. 10:256–266. 2013. View Article : Google Scholar : PubMed/NCBI
60	Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J and Wei X: Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct Target Ther. 4:622019. View Article : Google Scholar : PubMed/NCBI
61	Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 10:783–791. 2020.PubMed/NCBI
62	Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, et al: Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood. 136:2881–2892. 2020. View Article : Google Scholar : PubMed/NCBI
63	Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, Banet A, Lapusan S, Sestilli S, Corre E, et al: COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 55:2180–2184. 2020. View Article : Google Scholar : PubMed/NCBI
64	Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M, et al: A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. J Hematol Oncol. 13:942020. View Article : Google Scholar : PubMed/NCBI
65	Wang LQ, Tan Su Yin E, Wei GQ, Hu YX, Nagler A and Huang H: Weathering the storm: COVID-19 infection in patients with hematological malignancies. J Zhejiang Univ Sci B. 21:921–939. 2020. View Article : Google Scholar : PubMed/NCBI
66	Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ and Prescott HC: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 324:782–793. 2020. View Article : Google Scholar : PubMed/NCBI
67	Vlachakis D, Papakonstantinou E, Mitsis T, Pierouli K, Diakou I, Chrousos G and Bacopoulou F: Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. Food Chem Toxicol. 146:1118052020. View Article : Google Scholar : PubMed/NCBI
68	Psaltopoulou T, Sergentanis TN, Pappa V, Politou M, Terpos E, Tsiodras S, Pavlakis GN and Dimopoulos MA: The emerging role of convalescent plasma in the treatment of COVID-19. Hemasphere. 4:e4092020. View Article : Google Scholar : PubMed/NCBI
69	Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, et al: Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med. 26:1708–1713. 2020. View Article : Google Scholar : PubMed/NCBI
70	Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B and Sève P: Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 19:1025672020. View Article : Google Scholar : PubMed/NCBI
71	Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G and Dimopoulos MA: Hematological findings and complications of COVID-19. Am J Hematol. 95:834–847. 2020. View Article : Google Scholar : PubMed/NCBI
72	Calina D, Hartung T, Docea AO, Spandidos DA, Egorov AM, Shtilman MI, Carvalho F and Tsatsakis A: COVID-19 vaccines: Ethical framework concerning human challenge studies. Daru. 28:807–812. 2020. View Article : Google Scholar : PubMed/NCBI
73	Hernández AF, Calina D, Poulas K, Docea AO and Tsatsakis AM: Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicol Rep. 8:871–879. 2021. View Article : Google Scholar : PubMed/NCBI
74	Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, et al: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 18:313–319. 2021. View Article : Google Scholar : PubMed/NCBI
75	Gosain R, Abdou Y, Singh A, Rana N, Puzanov I and Ernstoff MS: COVID-19 and cancer: A comprehensive review. Curr Oncol Rep. 22:532020. View Article : Google Scholar : PubMed/NCBI
76	García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas J, Gil-Manso R, Kwon M, Sánchez-Godoy P, et al: Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J Hematol Oncol. 13:1332020. View Article : Google Scholar : PubMed/NCBI
77	Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, Anderson KC, Goldberg AD, Pennell NA, Niemeyer CM, et al: Outcomes of patients with hematologic malignancies and COVID-19: A report from the ASH research collaborative data Hub. Blood Adv. 4:5966–5975. 2020. View Article : Google Scholar : PubMed/NCBI
78	ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, Mohmed S, Alshaibani A, Cesaro S, Abd El-Aziz N, et al: The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. Jul 30–2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
79	He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, et al: COVID-19 in persons with haematological cancers. Leukemia. 34:1637–1645. 2020. View Article : Google Scholar : PubMed/NCBI
80	Kuderer NM, Hill JA, Carpenter PA and Lyman GH: Challenges and opportunities for COVID-19 vaccines in patients with cancer. Cancer Invest. 39:205–213. 2021. View Article : Google Scholar : PubMed/NCBI
81	Luker GD and Boettcher AN: Impact of COVID-19 on clinical care and research in cancer imaging: Where we are now. Radiol Imaging Cancer. 3:e2100032021. View Article : Google Scholar : PubMed/NCBI
82	Vlachakis D, Fakourelis P, Megalooikonomou V, Makris C and Kossida S: DrugOn: A fully integrated pharmacophore modeling and structure optimization toolkit. PeerJ. 3:e7252015. View Article : Google Scholar : PubMed/NCBI
83	Fong D, San Nicolò KO, Alber M and Mitterer M: Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers. Wien Klin Wochenschr. 133:359–363. 2021. View Article : Google Scholar : PubMed/NCBI
84	Cavalcanti IDL and Soares JCS: Impact of COVID-19 on cancer patients: A review. Asia Pac J Clin Oncol. 17:186–192. 2021. View Article : Google Scholar : PubMed/NCBI
85	Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, et al: Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 31:894–901. 2020. View Article : Google Scholar : PubMed/NCBI
86	Levy I, Sharf G, Norman S and Tadmor T: The impact of COVID-19 on patients with hematological malignancies: The mixed-method analysis of an Israeli national survey. Support Care Cancer. 1–9. 2021.(Epub ahead of print).